STOCK TITAN

Eli Lilly (NYSE: LLY) discloses 8.4M-share beneficial stake in Ionetix

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Eli Lilly and Company reports ownership of common stock of Ionetix Corp, a Delaware corporation with principal offices in Lansing, Michigan. Eli Lilly beneficially owns 8,411,397 shares of Ionetix common stock, representing 7.98% of the class.

Eli Lilly has sole power to vote and to dispose of all 8,411,397 shares, with no shared voting or dispositive power disclosed. The filing is signed by Christopher Anderson, Vice President – Leader of Corporate Securities and Assistant Corporate Secretary, on July 24, 2026.

Positive

  • None.

Negative

  • None.
Beneficial ownership 8,411,397 shares Common stock of Ionetix Corp beneficially owned by Eli Lilly
Ownership percentage 7.98% Percent of Ionetix Corp common stock class owned by Eli Lilly
Sole voting power 8,411,397 shares Shares of Ionetix over which Eli Lilly has sole power to vote
Sole dispositive power 8,411,397 shares Shares of Ionetix over which Eli Lilly has sole power to dispose
Par value per share $0.0001 per share Par value of Ionetix Corp common stock held by Eli Lilly
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 8,411,397"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power financial
"Sole Voting Power 8,411,397.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole Dispositive Power 8,411,397.00 8 | Shared Dispositive Power 0.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G regulatory
"form_type: "SCHEDULE 13G" in the filing metadata"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Ionetix Corp shares are reported as owned by Eli Lilly in this Schedule 13G?

Eli Lilly reports beneficial ownership of 8,411,397 Ionetix Corp common shares. It has sole power to vote and dispose of these 8,411,397 shares, with no shared authority indicated.

Does Eli Lilly share voting power over Ionetix Corp (LLY) shares in this filing?

No. Eli Lilly reports sole voting power over 8,411,397 shares of Ionetix Corp and no shared voting power. It likewise reports sole dispositive power over the same number of shares.

Who signed the Schedule 13G reporting Eli Lilly’s Ionetix Corp holdings?

The Schedule 13G is signed by Christopher Anderson, Vice President – Leader of Corporate Securities and Assistant Corporate Secretary of Eli Lilly, dated July 24, 2026.





000000000

(CUSIP Number)
04/09/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



ELI LILLY & Co
Signature:/s/ Christopher Anderson
Name/Title:Vice President - Leader of Corporate Securities and Assistant Corporate Secretary
Date:07/24/2026